Afuco™ Anti-VEGFA ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-011) (CAT#: AFC-TAB-011)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human VEGF is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is a humanized monoclonal antibody that produces angiogenesis inhibition by inhibiting vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer.
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.

(Neuronal cells
Staining:
Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/
membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/39240/82308_B_7_5.jpg

(Glandular cells
Staining:
Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/
membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/39240/82308_B_1_5.jpg

(Glandular cells
Staining:
High
Intensity: Strong
Quantity:>75%
Location: Cytoplasmic/
membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/39240/82308_A_7_3.jpg

(Cholangiocytes
Staining:
Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/
membranous
Hepatocytes
Staining:
High
Intensity: Strong
Quantity:>75%
Location: Cytoplasmic/
membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/39240/82308_A_8_4.jpg

(Cells in glomeruli
Staining:
Medium
Intensity: Moderate
Quantity: 75%-25%
Location: Cytoplasmic/
membranous
Cells in tubules
Staining:
Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/
membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/39240/82308_A_9_5.jpg

(Leydig cells
Staining:
High
Intensity: Strong
Quantity:>75%)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/39240/82308_A_5_6.jpg

(Non-germinal center cells
Staining:
Medium
Intensity: Strong
Quantity: <25%
Location: Cytoplasmic/
membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/39240/82308_A_7_8.jpg

(Cell lines ordered by descending RNA expression order.)
* https://v21.proteinatlas.org/ENSG00000112715-VEGFA

(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000112715-VEGFA
Specifications
- Immunogen
- Purified intact human VEGF
- Host Species
- Human
- Derivation
- Humanized (from mouse)
- Type
- ADCC enhanced antibody
- Species Reactivity
- Human
- Applications
- FC, IP, ELISA, Neut, FuncS, IF
- Conjugate
- Unconjugated
- Trade name
- Bevacizumab
- Generic Name
- Bevacizumab
- Related Disease
- Colorectal cancers, metastatic
Product Property
- Purity
- >95% by SDS-PAGE
- Storage
- Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- VEGFA; vascular endothelial growth factor A; vascular endothelial growth factor, VEGF; VEGF A; VPF; vascular permeability factor; VEGF; MVCD1;
- Gene ID
- 7422
- UniProt ID
- P15692
Related Resources
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Bevacizumab"
Anti-Human VEGF Recombinant Antibody (Bevacizumab)Recombinant monoclonal antibody to Human VEGF is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is licensed to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney and ovarian. Bevacizumab is a humanized monoclonal antibody that produces angiogenesis inhibition by inhibiting vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer.
See other products for "VEGFA"
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-H73 | Anti-Human VEGFA Recombinant Antibody (TAB-H73) | WB, FC, IP, ELISA, Neut, FuncS, IF | VH - C-kappa - CH2 - CH3 _ V-lambda - CH1 _ H-GAMMA-1 _ L-kappa |
TAB-011 | Anti-Human VEGF Recombinant Antibody (Bevacizumab) | FC, IP, ELISA, Neut, FuncS, IF, ICC | IgG1 - kappa |
TAB-012-F(E) | Anti-Human VEGF Recombinant Antibody Fab Fragment (TAB-012-F(E)) | IP, IF, FuncS, FC, Neut, ELISA, IHC | Fab - G1 - kappa |
TAB-307CQ | Human Anti-VEGFA Recombinant Antibody (TAB-307CQ) | Inhib | Human IgG |
TAB-307CQ-F(E) | Human Anti-VEGFA Recombinant Antibody; Fab Fragment (TAB-307CQ-F(E)) | ELISA, Neut | Humanized Fab |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for AFC-TAB-011. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: Neut, ELISA, IF, IP, FuncS, FC, IHC
Application: FuncS, IF, Neut, ELISA, FC, IP, IHC
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: FC, IHC, FuncS, Inhib, Cyt
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: WB, ELISA, FC, IP, FuncS, IF, Neut
Application: FC, IP, ELISA, Neut, FuncS, IF, ICC
Application: WB, ELISA, FuncS
Application: Neut, Inhib, FC, ELISA
Application: ELISA, WB, FC
Application: FC
Application: ELISA, FC, FuncS
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.